• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > About > Annual reports

2023 ANNUAL REPORT

Equity at the heart
of medical innovation

2023 ANNUAL REPORT
2023 FINANCIAL REPORT
  • FOREWORD
  • HIGHLIGHTS
  • 2023 IN NUMBERS
  • DNDi WORLDWIDE
  • OUR PROGRESS
  • R&D PORTFOLIO
  • PARTNERS
  • PERFORMANCE
  • THANKS

If there is a single highlight to look back on from 2023, it is the phenomenal power of partnership – the highlight of every one of our 20 years.

Foreword

2023 marked 20 years since our founding partners established DNDi, initiating an experiment in innovation and collaborative, not-for-profit pharmaceutical R&D centred on the needs of neglected patients. Throughout the year, we were grateful for the many opportunities to join with partners – in Latin America, East and West Africa, South and South-East Asia, Japan, North America, and Europe – to celebrate our collective successes in putting equity at the heart of medical innovation.

We also seized upon our anniversary milestone to look ahead. While the future may increasingly be defined by the climate crisis, geopolitical uncertainty, and the inevitability of new pandemics, it will also be shaped by the tremendous potential for scientific progress and medical innovation that transforms lives and livelihoods.

READ MORE

Highlights

Innovating to eliminate neglected diseases
DISCOVER

Highlights

Confronting the neglect of women and children in R&D​
DISCOVER

Highlights

Responding to the climate crisis
DISCOVER

Highlights

Preparing for future pandemics
DISCOVER
20 YEARS OF DNDi
FIND OUT MORE
OUR STORY IN FILM
WATCH THE VIDEO

2023 in numbers

31
Projects

in our R&D portfolio, and an additional 14 projects in the treatment access phase

26
Clinical trials

in 8 disease areas, including 16 trials testing new chemical entities

4,472
Patients

enrolled in active DNDi clinical studies

5:1
Ratio
of partner staff vs DNDi staff* worldwide

*Staff in full-time equivalents (FTEs)

35
Nationalities

represented among DNDi employees on 5 continents

DISCOVER MORE

DNDi WORLDWIDE

VOICES
Sleeping sickness
Dr Westain Nyirenda
Northern Malawi
"T.b. rhodesiense sleeping sickness is a terrifying disease, killing quickly if untreated. A simpler, safer oral treatment will help us save many lives."
Learn about our progress
Leishmaniasis
Jorge
Santa Fe de Antioquia, Colombia
"There was one time they applied the injection right in the wound. And it hurts a lot."
Learn about our progress
Leishmaniasis
Selena with her daughter, Tegla
Amudat District, Uganda
"She was so young back then. If there was a simpler treatment instead of injections, that would have made the experience much better – but I know that day is coming."
Learn about our progress
Chagas disease
Sara
Colombia
"The doctor explained that Chagas disease affects the organs and the heart. Because I was pregnant, she couldn’t treat me at that time."
Learn about our progress
Filaria: river blindness
Akoyo
Democratic Republic of the Congo
"I depend totally on my wife. She feeds and dresses me, and she also doesn’t have a job. After I lost my sight, we couldn’t send any of our children to school."
Learn about our progress
Mycetoma
Meles
Amhara Region of Ethiopia
"I am slowly losing hope for the future that I was looking forward to. What spouse will want a partner who cannot support his family?"
Learn about our progress
Dengue
Letícia
Rio de Janeiro, Brazil
"I had dengue three times. The last time, the pain in my body was unbearable – in my joints, behind my eyes – all I could do was lie down. I was vomiting and had a fever. If there was a treatment, I would have taken it when my symptoms started. I wouldn’t have suffered so much."
Learn about our progress
HIV
Ida Oliphant
Cape Town, South Africa
"It would make a huge difference to be able to administer flucytosine only two times per day instead of four, especially as we have so many patients to look after in our hospitals. And it would also help encourage patients to complete their full course of treatment once they return home."
Learn about our progress
Hepatitis C
Shahrudin
Rio de Janeiro, Brazil
"I did not know about the disease when the doctor mentioned that they suspected I had hepatitis C. I was told that it can attack the liver at any time, but by then it might be too late. I was very shocked and scared."
Learn about our progress

DNDi WORLDWIDE

Clinical sites

  • Sleeping sickness
  • Leishmaniasis
  • Chagas disease
  • Filaria: River blindness
  • Mycetoma
  • HIV
  • Hepatitis C
  • COVID-19
  • R&D AND ACCESS PARTNERS
  • DNDi OFFICES
  • FOUNDING PARTNERS
  • COUNTRIES WITH DNDi ACTIVITIES
LEARN ABOUT OUR PROGRESS
SLEEPING SICKNESS
LEISHMANIASIS
CHAGAS DISEASE​
FILARIA: RIVER BLINDNESS​
MYCETOMA​
DENGUE
HIV​
HEPATITIS C

RESEARCH & DEVELOPMENT PORTFOLIO

R&D PORTFOLIO

Acting as a ‘conductor of a virtual orchestra’, we collaborate with research partners around the world at all stages of the R&D process.

Our R&D portfolio includes 9 disease areas and 45 projects, 20 of which are focused on identifying or developing new chemical entities.

EXPLORE PORTFOLIO
Partners

DNDi’s worldwide footprint is anchored in endemic countries.

FIND OUT MORE
Performance

88% of 2023 DNDi expenditure was for our social mission.

FIND OUT MORE

A WORD OF THANKS

DNDi has delivered 13 new treatments for six neglected diseases since 2003.

OUR DONORS
OUR PARTNERS

Photo credits: Brent Stirton/Getty Images for DNDi, Matt Bouch-DNDi, Paul Kamau-DNDi, Fábio Nascimento-DNDi, Lameck Ododo-DNDi, Ariane Mawaffo-DNDi, Scholars-DNDi, Sydelle Willow Smith-DNDi, Ana Ferreira-DNDi, Brent Stirton/Getty Images, Karin Schermbrucker-DNDi, Kumerra Gemechu-DNDi, Abang Amirrul Hadi-DNDi, Lucas Tavares-DNDi

Stay connected

Get our latest news, personal stories, research articles, and job opportunities.

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
Sleeping sickness
Dr Westain Nyirenda
Northern Malawi
"T.b. rhodesiense sleeping sickness is a terrifying disease, killing quickly if untreated. A simpler, safer oral treatment will help us save many lives."
Learn about our progress
Leishmaniasis
Jorge
Santa Fe de Antioquia, Colombia
"There was one time they applied the injection right in the wound. And it hurts a lot."
Learn about our progress
Leishmaniasis
Selena with her daughter, Tegla
Amudat District, Uganda
"She was so young back then. If there was a simpler treatment instead of injections, that would have made the experience much better – but I know that day is coming."
Learn about our progress
Chagas disease
Sara
Colombia
"The doctor explained that Chagas disease affects the organs and the heart. Because I was pregnant, she couldn’t treat me at that time."
Learn about our progress
Filaria: river blindness
Akoyo
Democratic Republic of the Congo
"I depend totally on my wife. She feeds and dresses me, and she also doesn’t have a job. After I lost my sight, we couldn’t send any of our children to school."
Learn about our progress
Mycetoma
Meles
Amhara Region of Ethiopia
"I am slowly losing hope for the future that I was looking forward to. What spouse will want a partner who cannot support his family?"
Learn about our progress
Dengue
Letícia
Rio de Janeiro, Brazil
"I had dengue three times. The last time, the pain in my body was unbearable – in my joints, behind my eyes – all I could do was lie down. I was vomiting and had a fever. If there was a treatment, I would have taken it when my symptoms started. I wouldn’t have suffered so much."
Learn about our progress
HIV
Ida Oliphant
Cape Town, South Africa
"It would make a huge difference to be able to administer flucytosine only two times per day instead of four, especially as we have so many patients to look after in our hospitals. And it would also help encourage patients to complete their full course of treatment once they return home."
Learn about our progress
Hepatitis C
Shahrudin
Rio de Janeiro, Brazil
"I did not know about the disease when the doctor mentioned that they suspected I had hepatitis C. I was told that it can attack the liver at any time, but by then it might be too late. I was very shocked and scared."
Learn about our progress